{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T15:28:10Z","timestamp":1743002890035,"version":"3.40.3"},"publisher-location":"Cham","reference-count":168,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030445171"},{"type":"electronic","value":"9783030445188"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-44518-8_8","type":"book-chapter","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T19:02:25Z","timestamp":1593111745000},"page":"117-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chimeric Antigen Receptors for the Tumour Microenvironment"],"prefix":"10.1007","author":[{"given":"Rosemary","family":"Habib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Nagrial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Micklethwaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitha","family":"Gowrishankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K (2018) IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 36:346\u2013351","journal-title":"Nat Biotechnol"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/eji.1830261006","volume":"26","author":"L Alvarez-Vallina","year":"1996","unstructured":"Alvarez-Vallina L, Hawkins RE (1996) Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 26:2304\u20132309","journal-title":"Eur J Immunol"},{"key":"8_CR3","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, Van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ (2018) Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep 23:2130\u20132141","journal-title":"Cell Rep"},{"key":"8_CR4","first-page":"3190","volume":"130","author":"V Baldan","year":"2017","unstructured":"Baldan V, Ghongane P, Kokalaki E, Lim WC, Onuoha S, Cordoba SP, Thomas S, Pule M (2017) A dominant negative SHP-2 which abrogates PD-1 signalling pathways and restores function of cytotoxic CAR T cells. Blood 130:3190","journal-title":"Blood"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/path.3029","volume":"226","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR (2012) The chemokine system and cancer. J Pathol 226:148\u2013157","journal-title":"J Pathol"},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","volume":"127","author":"PA Beavis","year":"2017","unstructured":"Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK (2017) Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest 127:929\u2013941","journal-title":"J Clin Invest"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"72961","DOI":"10.18632\/oncotarget.12150","volume":"7","author":"A Beldi-Ferchiou","year":"2016","unstructured":"Beldi-Ferchiou A, Lambert M, Dogniaux S, Vely F, Vivier E, Olive D, Dupuy S, Levasseur F, Zucman D, Lebbe C, Sene D, Hivroz C, Caillat-Zucman S (2016) PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 7:72961\u201372977","journal-title":"Oncotarget"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/neuonc\/nox182","volume":"20","author":"K Bielamowicz","year":"2018","unstructured":"Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, Wu MF, Orange JS, Sumazin P, Man TK, Joseph SK, Hegde M, Ahmed N (2018) Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro-Oncology 20:506\u2013518","journal-title":"Neuro-Oncology"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","volume":"64","author":"RA Burga","year":"2015","unstructured":"Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, Dematteo RP, Ayala A, Joseph Espat N, Junghans RP, Katz SC (2015) Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother 64:817\u2013829","journal-title":"Cancer Immunol Immunother"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249\u2013257","journal-title":"Nature"},{"key":"8_CR11","doi-asserted-by":"crossref","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G (2015) Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21(5):524\u2013529 https:\/\/doi.org\/10.1038\/nm.3833. Epub 2015 Apr 13","DOI":"10.1038\/nm.3833"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-12-3558","volume":"73","author":"YH Chang","year":"2013","unstructured":"Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D (2013) A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 73:1777\u20131786","journal-title":"Cancer Res"},{"key":"8_CR13","first-page":"e1273302","volume":"6","author":"N Chen","year":"2016","unstructured":"Chen N, Morello A, Tano Z, Adusumilli PS (2016a) CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy. Onco Targets Ther 6:e1273302","journal-title":"Onco Targets Ther"},{"key":"8_CR14","doi-asserted-by":"publisher","first-page":"27764","DOI":"10.18632\/oncotarget.8526","volume":"7","author":"X Chen","year":"2016","unstructured":"Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, Chen L, Wang Y, Wang H, Yi L, Elder JB, Wang QE, He X, Kaur B, Chiocca EA, Yu J (2016b) A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget 7:27764\u201327777","journal-title":"Oncotarget"},{"key":"8_CR15","doi-asserted-by":"publisher","first-page":"e19028","DOI":"10.1200\/JCO.2019.37.15_suppl.e19028","volume":"37","author":"T Chen","year":"2019","unstructured":"Chen T, Yuan Y, Huang L, Pu C, Ding T, Xiao X, Cao Z, Wu T, Ding L, Sun H, Wu Z, Xiao L, Zhang X (2019) Dominant-negative PD1-armored CART cells induce remission in refractory diffuse large B-cell lymphoma (DLBCL) patients. J Clin Oncol 37:e19028","journal-title":"J Clin Oncol"},{"key":"8_CR16","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126:3130\u20133144","journal-title":"J Clin Invest"},{"key":"8_CR17","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","volume":"18","author":"D Chinnasamy","year":"2012","unstructured":"Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, Rosenberg SA (2012) Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 18:1672\u20131683","journal-title":"Clin Cancer Res"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski M, Abken H (2017) CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors. Cell Rep 21:3205\u20133219","journal-title":"Cell Rep"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H (2014) Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 257:83\u201390","journal-title":"Immunol Rev"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/cmi.2016.02","volume":"14","author":"BK Choi","year":"2017","unstructured":"Choi BK, Lee DY, Lee DG, Kim YH, Kim S-H, Oh HS, Han C, Kwon BS (2017) 4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8(+) T cell proliferation. Cell Mol Immunol 14:748\u2013757","journal-title":"Cell Mol Immunol"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","volume":"28","author":"J Chu","year":"2014","unstructured":"Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J (2014) CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28:917\u2013927","journal-title":"Leukemia"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"e0130518","DOI":"10.1371\/journal.pone.0130518","volume":"10","author":"M Condomines","year":"2015","unstructured":"Condomines M, Arnason J, Benjamin R, Gunset G, Plotkin J, Sadelain M (2015) Tumor-targeted human T cells expressing CD28-based chimeric antigen receptors circumvent CTLA-4 inhibition. PLoS One 10:e0130518","journal-title":"PLoS One"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33:780\u2013788","journal-title":"J Immunother"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","volume":"8","author":"ML Davila","year":"2013","unstructured":"Davila ML, Kloss CC, Gunset G, Sadelain M (2013) CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One 8:e61338","journal-title":"PLoS One"},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"15819","DOI":"10.1038\/s41598-017-15920-6","volume":"7","author":"G De Velasco","year":"2017","unstructured":"De Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sep\u00falveda JM, Prado-Vazquez G, Arevalillo JM, Zapater-Moros A, Navarro H, Lopez-Vacas R, Manneh R, Otero I, Villacampa F, Paramio JM, Vara JAF, Castellano D (2017) Urothelial cancer proteomics provides both prognostic and functional information. Sci Rep 7:15819","journal-title":"Sci Rep"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1006\/mthe.2002.0611","volume":"5","author":"SG Deeks","year":"2002","unstructured":"Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM (2002) A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5:788\u2013797","journal-title":"Mol Ther"},{"key":"8_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","volume":"51","author":"P Dhar","year":"2018","unstructured":"Dhar P, Wu JD (2018) NKG2D and its ligands in cancer. Curr Opin Immunol 51:55\u201361","journal-title":"Curr Opin Immunol"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113:6392","journal-title":"Blood"},{"key":"8_CR29","first-page":"27","volume":"10","author":"Z Eshhar","year":"1990","unstructured":"Eshhar Z, Gross G (1990) Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach. Br J Cancer Suppl 10:27\u201329","journal-title":"Br J Cancer Suppl"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1582-4934.2011.01343.x","volume":"16","author":"R Esser","year":"2012","unstructured":"Esser R, Muller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schonfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS (2012) NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 16:569\u2013581","journal-title":"J Cell Mol Med"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-019-0994-2","volume":"18","author":"ME Fiori","year":"2019","unstructured":"Fiori ME, DI Franco S, Villanova L, Bianca P, Stassi G, DE Maria R (2019) Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer 18:70","journal-title":"Mol Cancer"},{"key":"8_CR32","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31:822\u2013826","journal-title":"Nat Biotechnol"},{"key":"8_CR33","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/JCO.2017.35.15_suppl.3025","volume":"35","author":"J Galon","year":"2017","unstructured":"Galon J, Rossi J, Turcan S, Danan C, Locke FL, Neelapu SS, Miklos DB, Bartlett NL, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman J, Reagan PM, Lekakis LJ, Unabia S, Go WY, Wiezorek JS, Bot A (2017) Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19). J Clin Oncol 35:3025\u20133025","journal-title":"J Clin Oncol"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00335-018-9756-5","volume":"29","author":"K Gowrishankar","year":"2018","unstructured":"Gowrishankar K, Birtwistle L, Micklethwaite K (2018) Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Mamm Genome 29:739\u2013756","journal-title":"Mamm Genome"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schonfeld K, Koch J, Dotti G, Heslop HE, Gottschalk S, Wels WS, Baker ML, Ahmed N (2013) TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2:e105","journal-title":"Mol Ther Nucleic Acids"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 86:10024\u201310028","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309\u2013322","journal-title":"Cancer Cell"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.celrep.2017.10.104","volume":"21","author":"E Hawila","year":"2017","unstructured":"Hawila E, Razon H, Wildbaum G, Blattner C, Sapir Y, Shaked Y, Umansky V, Karin N (2017) CCR5 directs the mobilization of CD11b(+)Gr1(+)Ly6C(low) polymorphonuclear myeloid cells from the bone marrow to the blood to support Tumor development. Cell Rep 21:2212\u20132222","journal-title":"Cell Rep"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.2147\/OTT.S170385","volume":"11","author":"Y He","year":"2018","unstructured":"He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR (2018) TIM-3, a promising target for cancer immunotherapy. Onco Targets Ther 11:7005\u20137009","journal-title":"Onco Targets Ther"},{"key":"8_CR41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/emboj.2012.333","volume":"32","author":"B Heemskerk","year":"2013","unstructured":"Heemskerk B, Kvistborg P, Schumacher TN (2013) The cancer antigenome. EMBO J 32:194\u2013203","journal-title":"EMBO J"},{"key":"8_CR42","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/mt.2013.185","volume":"21","author":"M Hegde","year":"2013","unstructured":"Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Yvon E, Ahmed N (2013) Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 21:2087\u20132101","journal-title":"Mol Ther"},{"key":"8_CR43","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N (2016) Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest 126:3036\u20133052","journal-title":"J Clin Invest"},{"key":"8_CR44","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/mt.2013.192","volume":"21","author":"AA Hombach","year":"2013","unstructured":"Hombach AA, Rappl G, Abken H (2013) Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \u201csuper-stimulation\u201d. Mol Ther 21:2268\u20132277","journal-title":"Mol Ther"},{"key":"8_CR45","first-page":"E118","volume":"108","author":"JK Hu","year":"2011","unstructured":"Hu JK, Kagari T, Clingan JM, Matloubian M (2011) Expression of chemokine receptor CXCR3 on T cells affects the balance between effector and memory CD8 T-cell generation. Proc Natl Acad Sci 108:E118","journal-title":"Proc Natl Acad Sci"},{"key":"8_CR46","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","volume":"10","author":"W Hu","year":"2019","unstructured":"Hu W, Wang G, Huang D, Sui M, Xu Y (2019a) Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol 10:1205","journal-title":"Front Immunol"},{"key":"8_CR47","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","volume":"68","author":"W Hu","year":"2019","unstructured":"Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, Ma X, Wei F (2019b) CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother 68:365\u2013377","journal-title":"Cancer Immunol Immunother"},{"key":"8_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2015.07.039","volume":"368","author":"L Hui","year":"2015","unstructured":"Hui L, Chen Y (2015) Tumor microenvironment: sanctuary of the devil. Cancer Lett 368:7\u201313","journal-title":"Cancer Lett"},{"key":"8_CR49","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","volume":"106","author":"C Imai","year":"2005","unstructured":"Imai C, Iwamoto S, Campana D (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106:376","journal-title":"Blood"},{"key":"8_CR50","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"BA Irving","year":"1991","unstructured":"Irving BA, Weiss A (1991) The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64:891\u2013901","journal-title":"Cell"},{"key":"8_CR51","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R (2012) Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 30:837\u2013842","journal-title":"J Clin Oncol"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","volume":"169","author":"Y Ishino","year":"1987","unstructured":"Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A (1987) Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol 169:5429\u20135433","journal-title":"J Bacteriol"},{"key":"8_CR53","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","volume":"21","author":"M Jamal-Hanjani","year":"2015","unstructured":"Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C (2015) Translational implications of tumor heterogeneity. Clin Cancer Res 21:1258\u20131266","journal-title":"Clin Cancer Res"},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41467-019-09018-y","volume":"10","author":"HJ Johansson","year":"2019","unstructured":"Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred O, Boekel J, Sauer T, Zhao W, Nord S, Hoglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF, Schlichting E, Naume B, Consortia Oslo Breast Cancer Research Consortium, Luders T, Borgen E, Kristensen VN, Russnes HG, Lingjaerde OC, Mills GB, Sahlberg KK, Borresen-Dale AL, Lehtio J (2019) Breast cancer quantitative proteome and proteogenomic landscape. Nat Commun 10:1600","journal-title":"Nat Commun"},{"key":"8_CR55","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19:5636\u20135646","journal-title":"Clin Cancer Res"},{"key":"8_CR56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74\u201380","journal-title":"Science"},{"key":"8_CR57","doi-asserted-by":"publisher","first-page":"39833","DOI":"10.1038\/srep39833","volume":"7","author":"A Juillerat","year":"2017","unstructured":"Juillerat A, Marechal A, Filhol JM, Valogne Y, Valton J, Duclert A, Duchateau P, Poirot L (2017) An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep 7:39833","journal-title":"Sci Rep"},{"key":"8_CR58","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2217\/imt.14.123","volume":"7","author":"M Kalaitsidou","year":"2015","unstructured":"Kalaitsidou M, Kueberuwa G, Schutt A, Gilham DE (2015) CAR T-cell therapy: toxicity and the relevance of preclinical models. Immunotherapy 7:487\u2013497","journal-title":"Immunotherapy"},{"key":"8_CR59","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fphar.2014.00123","volume":"5","author":"RT Kendall","year":"2014","unstructured":"Kendall RT, Feghali-Bostwick CA (2014a) Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol 5:123\u2013123","journal-title":"Front Pharmacol"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fphar.2014.00123","volume":"5","author":"RT Kendall","year":"2014","unstructured":"Kendall RT, Feghali-Bostwick CA (2014b) Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol 5:123","journal-title":"Front Pharmacol"},{"key":"8_CR61","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.bbmt.2015.11.291","volume":"22","author":"SS Kenderian","year":"2016","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Kim M, Porter DL, June CH, Gill S (2016) Identification of PD1 and TIM3 as checkpoints that limit chimeric antigen receptor T cell efficacy in leukemia. Biol Blood Marrow Transplant 22:S19\u2013S21","journal-title":"Biol Blood Marrow Transplant"},{"key":"8_CR62","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","volume":"3","author":"HT Khong","year":"2002","unstructured":"Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of \u201ctumor escape\u201d phenotypes. Nat Immunol 3:999\u20131005","journal-title":"Nat Immunol"},{"key":"8_CR63","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.phrs.2015.08.004","volume":"100","author":"T Kitamura","year":"2015","unstructured":"Kitamura T, Pollard JW (2015) Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacol Res 100:266\u2013270","journal-title":"Pharmacol Res"},{"key":"8_CR64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31:71\u201375","journal-title":"Nat Biotechnol"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH (2018) Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther 26:1855\u20131866","journal-title":"Mol Ther"},{"key":"8_CR66","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","volume":"13","author":"M Koneru","year":"2015","unstructured":"Koneru M, O'cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ (2015a) A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 13:102","journal-title":"J Transl Med"},{"key":"8_CR67","first-page":"e994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ (2015b) IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Onco Targets Ther 4:e994446","journal-title":"Onco Targets Ther"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:10501","journal-title":"Nat Commun"},{"key":"8_CR69","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","volume":"168","author":"AW Lambert","year":"2017","unstructured":"Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168:670\u2013691","journal-title":"Cell"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s41467-018-03573-6","volume":"9","author":"L Latonen","year":"2018","unstructured":"Latonen L, Afyounian E, Jylh\u00e4 A, N\u00e4ttinen J, Aapola U, Annala M, Kivinummi KK, Tammela TTL, Beuerman RW, Uusitalo H, Nykter M, Visakorpi T (2018) Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun 9:1176","journal-title":"Nat Commun"},{"key":"8_CR71","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fonc.2018.00237","volume":"8","author":"T Le Bourgeois","year":"2018","unstructured":"Le Bourgeois T, Strauss L, Aksoylar HI, Daneshmandi S, Seth P, Patsoukis N, Boussiotis VA (2018) Targeting T cell metabolism for improvement of cancer immunotherapy. Front Oncol 8:237","journal-title":"Front Oncol"},{"key":"8_CR72","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517\u2013528","journal-title":"Lancet"},{"key":"8_CR73","doi-asserted-by":"publisher","first-page":"676198","DOI":"10.1155\/2011\/676198","volume":"2011","author":"EM Levy","year":"2011","unstructured":"Levy EM, Roberti MP, Mordoh J (2011) Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011:676198","journal-title":"J Biomed Biotechnol"},{"key":"8_CR74","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nbt.4071","volume":"36","author":"S Li","year":"2018","unstructured":"Li S, Jiang Q, Liu S, Zhang Y, Tian Y, Song C, Wang J, Zou Y, Anderson GJ, Han J-Y, Chang Y, Liu Y, Zhang C, Chen L, Zhou G, Nie G, Yan H, Ding B, Zhao Y (2018) A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat Biotechnol 36:258","journal-title":"Nat Biotechnol"},{"key":"8_CR75","doi-asserted-by":"publisher","first-page":"759","DOI":"10.4049\/jimmunol.1401710","volume":"196","author":"MA Ligtenberg","year":"2016","unstructured":"Ligtenberg MA, Mougiakakos D, Mukhopadhyay M, Witt K, Lladser A, Chmielewski M, Riet T, Abken H, Kiessling R (2016) Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity. J Immunol 196:759\u2013766","journal-title":"J Immunol"},{"key":"8_CR76","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y, Moon EK (2016) A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res 76:1578\u20131590","journal-title":"Cancer Res"},{"key":"8_CR77","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00262-016-1877-7","volume":"65","author":"M Lopez","year":"2016","unstructured":"Lopez M, Ghidouche A, Rochas C, Godelaine D, Carrasco J, Colau D, Hames G, Montero-Julian FA, Coulie PG, Olive D (2016) Identification of a naturally processed HLA-A\u221702:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4. Cancer Immunol Immunother 65:1177\u20131188","journal-title":"Cancer Immunol Immunother"},{"key":"8_CR78","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1600-065X.2008.00760.x","volume":"228","author":"U Lorenz","year":"2009","unstructured":"Lorenz U (2009) SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev 228:342\u2013359","journal-title":"Immunol Rev"},{"key":"8_CR79","doi-asserted-by":"publisher","first-page":"e1004441","DOI":"10.1371\/journal.ppat.1004441","volume":"10","author":"M Luetke-Eversloh","year":"2014","unstructured":"Luetke-Eversloh M, Hammer Q, Durek P, Nordstrom K, Gasparoni G, Pink M, Hamann A, Walter J, Chang HD, Dong J, Romagnani C (2014) Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS Pathog 10:e1004441","journal-title":"PLoS Pathog"},{"key":"8_CR80","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL (2018) Tumor antigen escape from CAR T-cell therapy. Cancer Discov 8:1219\u20131226","journal-title":"Cancer Discov"},{"key":"8_CR81","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL (2019) CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res 25:2560\u20132574","journal-title":"Clin Cancer Res"},{"key":"8_CR82","doi-asserted-by":"crossref","unstructured":"Mardiana S, Solomon BJ, Darcy PK, Beavis PA (2019) Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Sci Transl Med 11","DOI":"10.1126\/scitranslmed.aaw2293"},{"key":"8_CR83","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK (2019) CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 10:128","journal-title":"Front Immunol"},{"key":"8_CR84","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507\u20131517","journal-title":"N Engl J Med"},{"key":"8_CR85","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, DE Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378:439\u2013448","journal-title":"N Engl J Med"},{"key":"8_CR86","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fonc.2019.00176","volume":"9","author":"NG Minutolo","year":"2019","unstructured":"Minutolo NG, Hollander EE, Powell DJ (2019) The emergence of universal immune receptor T cell therapy for cancer. Front Oncol 9:176","journal-title":"Front Oncol"},{"key":"8_CR87","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF (2017) Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther 25:249\u2013258","journal-title":"Mol Ther"},{"key":"8_CR88","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3389\/fimmu.2019.00379","volume":"10","author":"V Mollica Poeta","year":"2019","unstructured":"Mollica Poeta V, Massara M, Capucetti A, Bonecchi R (2019) Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol 10:379","journal-title":"Front Immunol"},{"key":"8_CR89","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","volume":"20","author":"EK Moon","year":"2014","unstructured":"Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Pure E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM (2014) Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 20:4262\u20134273","journal-title":"Clin Cancer Res"},{"key":"8_CR90","doi-asserted-by":"crossref","unstructured":"Morgan MA, Schambach A (2018) Engineering CAR-T cells for improved function against solid tumors. Front Immunol:9","DOI":"10.3389\/fimmu.2018.02493"},{"key":"8_CR91","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","volume":"164","author":"L Morsut","year":"2016","unstructured":"Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, Lim WA (2016) Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164:780\u2013791","journal-title":"Cell"},{"key":"8_CR92","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, Mcdermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, Mchenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290","journal-title":"N Engl J Med"},{"key":"8_CR93","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","volume":"57","author":"T Muller","year":"2008","unstructured":"Muller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS (2008) Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 57:411\u2013423","journal-title":"Cancer Immunol Immunother"},{"key":"8_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","volume":"39","author":"DH Munn","year":"2016","unstructured":"Munn DH, Bronte V (2016) Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol 39:1\u20136","journal-title":"Curr Opin Immunol"},{"key":"8_CR95","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.beha.2018.07.011","volume":"31","author":"R Nair","year":"2018","unstructured":"Nair R, Neelapu SS (2018) The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol 31:293\u2013298","journal-title":"Best Pract Res Clin Haematol"},{"key":"8_CR96","doi-asserted-by":"publisher","first-page":"TPS347","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS347","volume":"37","author":"V Narayan","year":"2019","unstructured":"Narayan V, Gladney W, Plesa G, Vapiwala N, Carpenter E, Maude SL, Lal P, Lacey SF, Melenhorst JJ, Sebro R, Farwell M, Hwang W-T, Moniak M, Gilmore J, Lledo L, Dengel K, Marshall A, Coughlin CM, June CH, Haas NB (2019) A phase I clinical trial of PSMA-directed\/TGF\u03b2-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. J Clin Oncol 37:TPS347\u2013TPS347","journal-title":"J Clin Oncol"},{"key":"8_CR97","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, Mcsweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544","journal-title":"N Engl J Med"},{"key":"8_CR98","first-page":"1723","volume":"150","author":"RP Negus","year":"1997","unstructured":"Negus RP, Stamp GW, Hadley J, Balkwill FR (1997) Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150:1723\u20131734","journal-title":"Am J Pathol"},{"key":"8_CR99","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1084\/jem.20120944","volume":"209","author":"J Ni","year":"2012","unstructured":"Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A (2012) Sustained effector function of IL-12\/15\/18-preactivated NK cells against established tumors. J Exp Med 209:2351\u20132365","journal-title":"J Exp Med"},{"key":"8_CR100","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"S Ninomiya","year":"2015","unstructured":"Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA (2015) Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125:3905\u20133916","journal-title":"Blood"},{"key":"8_CR101","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0165-2478(00)00243-1","volume":"74","author":"M Nouri-Shirazi","year":"2000","unstructured":"Nouri-Shirazi M, Banchereau J, Fay J, Palucka K (2000) Dendritic cell based tumor vaccines. Immunol Lett 74:5\u201310","journal-title":"Immunol Lett"},{"key":"8_CR102","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.immuni.2015.09.013","volume":"43","author":"TE O\u2019sullivan","year":"2015","unstructured":"O\u2019sullivan TE, Sun JC, Lanier LL (2015) Natural killer cell memory. Immunity 43:634\u2013645","journal-title":"Immunity"},{"key":"8_CR103","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D Ohlund","year":"2017","unstructured":"Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA (2017) Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214:579\u2013596","journal-title":"J Exp Med"},{"key":"8_CR104","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1586\/erv.12.107","volume":"11","author":"BM Olson","year":"2012","unstructured":"Olson BM, Mcneel DG (2012) Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Rev Vaccines 11:1315\u20131317","journal-title":"Expert Rev Vaccines"},{"key":"8_CR105","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-07-5211","volume":"14","author":"E Ostermann","year":"2008","unstructured":"Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, Kerjaschki D, Rettig WJ, Adolf GR (2008) Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 14:4584\u20134592","journal-title":"Clin Cancer Res"},{"key":"8_CR106","doi-asserted-by":"publisher","first-page":"E5454","DOI":"10.1073\/pnas.1607436113","volume":"113","author":"SV Pageon","year":"2016","unstructured":"Pageon SV, Tabarin T, Yamamoto Y, Ma Y, Nicovich PR, Bridgeman JS, Cohnen A, Benzing C, Gao Y, Crowther MD, Tungatt K, Dolton G, Sewell AK, Price DA, Acuto O, Parton RG, Gooding JJ, Rossy J, Rossjohn J, Gaus K (2016) Functional role of T-cell receptor nanoclusters in signal initiation and antigen discrimination. Proc Natl Acad Sci 113:E5454","journal-title":"Proc Natl Acad Sci"},{"key":"8_CR107","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ni1536","volume":"8","author":"P Pandiyan","year":"2007","unstructured":"Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ (2007) CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8:1353\u20131362","journal-title":"Nat Immunol"},{"key":"8_CR108","doi-asserted-by":"publisher","first-page":"C947","DOI":"10.1152\/ajpcell.00389.2001","volume":"282","author":"M Papetti","year":"2002","unstructured":"Papetti M, Herman IM (2002) Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282:C947\u2013C970","journal-title":"Am J Physiol Cell Physiol"},{"key":"8_CR109","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:449\u2013459","journal-title":"N Engl J Med"},{"key":"8_CR110","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/icb.2010.78","volume":"89","author":"HJ Pegram","year":"2011","unstructured":"Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH (2011) Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 89:216\u2013224","journal-title":"Immunol Cell Biol"},{"key":"8_CR111","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","volume":"72","author":"W Peng","year":"2012","unstructured":"Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizee G, Radvanyi L, Hwu P (2012) PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 72:5209\u20135218","journal-title":"Cancer Res"},{"key":"8_CR112","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ajh.24794","volume":"92","author":"LP Perera","year":"2017","unstructured":"Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, Waldmann TA, Perera P-Y (2017) Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am J Hematol 92:892\u2013901","journal-title":"Am J Hematol"},{"key":"8_CR113","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1158\/1078-0432.CCR-13-1016","volume":"20","author":"SK Perna","year":"2014","unstructured":"Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, Dotti G (2014) Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 20:131\u2013139","journal-title":"Clin Cancer Res"},{"key":"8_CR168","doi-asserted-by":"crossref","unstructured":"Prehn RT (1972) Science 176(4031):170\u2013171","DOI":"10.1126\/science.176.4031.170"},{"key":"8_CR114","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1741-7015-6-11","volume":"6","author":"PP Provenzano","year":"2008","unstructured":"Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ (2008) Collagen density promotes mammary tumor initiation and progression. BMC Med 6:11","journal-title":"BMC Med"},{"key":"8_CR115","doi-asserted-by":"crossref","unstructured":"Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., Ghorashian, S., Pinner, D., Ahsan, G., Gilmour, K., Lucchini, G., Inglott, S., Mifsud, W., Chiesa, R., Peggs, K. S., Chan, L., Farzeneh, F., Thrasher, A. J., Vora, A., Pule, M. & Veys, P. 2017. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells Sci Transl Med, eaaj2013 9","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"8_CR116","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/gutjnl-2018-316595","volume":"68","author":"D Raj","year":"2019","unstructured":"Raj D, Yang MH, Rodgers D, Hampton EN, Begum J, Mustafa A, Lorizio D, Garces I, Propper D, Kench JG, Kocher HM, Young TS, Aicher A, Heeschen C (2019) Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut 68:1052\u20131064","journal-title":"Gut"},{"key":"8_CR117","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y (2017a) Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 23:2255\u20132266","journal-title":"Clin Cancer Res"},{"key":"8_CR118","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.18632\/oncotarget.15218","volume":"8","author":"J Ren","year":"2017","unstructured":"Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, Zhao Y (2017b) A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 8:17002\u201317011","journal-title":"Oncotarget"},{"key":"8_CR119","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, Ma J, Nunez V, Shen J, Woods AK, Wright TM, Schultz PG, Kim CH, Young TS (2016) Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A 113:E459\u2013E468","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR120","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1152\/physrev.1996.76.1.69","volume":"76","author":"L Ronnov-Jessen","year":"1996","unstructured":"Ronnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76:69\u2013125","journal-title":"Physiol Rev"},{"key":"8_CR121","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3389\/fimmu.2018.02103","volume":"9","author":"A Rosewell Shaw","year":"2018","unstructured":"Rosewell Shaw A, Suzuki M (2018) Oncolytic viruses partner with T-cell therapy for solid tumor treatment. Front Immunol 9:2103","journal-title":"Front Immunol"},{"key":"8_CR122","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Rupp LJ, Morsut L, Walker WJ, Mcnally KA, Park JS, Lim WA (2016) Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164:770\u2013779","journal-title":"Cell"},{"key":"8_CR123","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A (2017) CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 7:737","journal-title":"Sci Rep"},{"key":"8_CR124","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1172\/JCI80010","volume":"125","author":"M Sadelain","year":"2015","unstructured":"Sadelain M (2015) CAR therapy: the CD19 paradigm. J Clin Invest 125:3392\u20133400","journal-title":"J Clin Invest"},{"key":"8_CR125","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3:388\u2013398","journal-title":"Cancer Discov"},{"key":"8_CR126","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187\u20132194","journal-title":"J Exp Med"},{"key":"8_CR127","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1080\/21645515.2019.1571893","volume":"15","author":"J Salas-Mckee","year":"2019","unstructured":"Salas-Mckee J, Kong W, Gladney WL, Jadlowsky JK, Plesa G, Davis MM, Fraietta JA (2019) CRISPR\/Cas9-based genome editing in the era of CAR T cell immunotherapy. Hum Vaccin Immunother 15:1126\u20131132","journal-title":"Hum Vaccin Immunother"},{"key":"8_CR128","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2326-6066.CIR-14-0192","volume":"3","author":"SP Santoro","year":"2015","unstructured":"Santoro SP, Kim S, Motz GT, Alatzoglou D, Li C, Irving M, Powell DJ Jr, Coukos G (2015) T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol Res 3:68\u201384","journal-title":"Cancer Immunol Res"},{"key":"8_CR129","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1479-5876-11-187","volume":"11","author":"PC Schuberth","year":"2013","unstructured":"Schuberth PC, Hagedorn C, Jensen SM, Gulati P, Van Den Broek M, Mischo A, Soltermann A, Jungel A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U (2013) Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med 11:187","journal-title":"J Transl Med"},{"key":"8_CR130","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ (2019) Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 16:372\u2013385","journal-title":"Nat Rev Clin Oncol"},{"key":"8_CR131","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","volume":"70","author":"RK Shrimali","year":"2010","unstructured":"Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA (2010) Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70:6171\u20136180","journal-title":"Cancer Res"},{"key":"8_CR132","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R, Castillo P, Liu H, Brenner MK, Metelitsa LS, Gottschalk S, Rooney CM (2017) Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov 7:1238\u20131247","journal-title":"Cancer Discov"},{"key":"8_CR133","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","volume":"16","author":"S Sivori","year":"2019","unstructured":"Sivori S, Vacca P, DEL Zotto G, Munari E, Mingari MC, Moretta L (2019) Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol 16:430\u2013441","journal-title":"Cell Mol Immunol"},{"key":"8_CR134","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, Stephan SB, Moffett HF, Mcknight LE, Ji W, Reiman D, Bonagofski E, Wohlfahrt ME, Pillai SPS, Stephan MT (2017) In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol 12:813\u2013820","journal-title":"Nat Nanotechnol"},{"key":"8_CR135","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5:1282\u20131295","journal-title":"Cancer Discov"},{"key":"8_CR136","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","volume":"7","author":"ER Suarez","year":"2016","unstructured":"Suarez ER, de Chang K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA (2016) Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget 7:34341\u201334355","journal-title":"Oncotarget"},{"key":"8_CR137","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1172\/JCI69589","volume":"123","author":"M Sukumar","year":"2013","unstructured":"Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L (2013) Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 123:4479\u20134488","journal-title":"J Clin Invest"},{"key":"8_CR138","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","volume":"23","author":"M Sukumar","year":"2016","unstructured":"Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, Klebanoff CA, Ji Y, Li P, Yu Z, Whitehill GD, Clever D, Eil RL, Palmer DC, Mitra S, Rao M, Keyvanfar K, Schrump DS, Wang E, Marincola FM, Gattinoni L, Leonard WJ, Muranski P, Finkel T, Restifo NP (2016) Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metab 23:63\u201376","journal-title":"Cell Metab"},{"key":"8_CR139","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nrd.2018.202","volume":"17","author":"J Tang","year":"2018","unstructured":"Tang J, Pearce L, O'donnell-Tormey J, Hubbard-Lucey VM (2018) Trends in the global immuno-oncology landscape. Nat Rev Drug Discov 17:922","journal-title":"Nat Rev Drug Discov"},{"key":"8_CR140","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119:3940\u20133950","journal-title":"Blood"},{"key":"8_CR141","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, Tykodi SS, Kebriaei P, Lee DA, Miller JC, Rebar EJ, Holmes MC, Jaenisch R, Champlin RE, Gregory PD, Cooper LJ (2013) Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122:1341\u20131349","journal-title":"Blood"},{"key":"8_CR142","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.4049\/jimmunol.155.2.1000","volume":"155","author":"AC Tran","year":"1995","unstructured":"Tran AC, Zhang D, Byrn R, Roberts MR (1995) Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J Immunol 155:1000\u20131009","journal-title":"J Immunol"},{"key":"8_CR143","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, Rosenberg SA (2013) Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 210:1125\u20131135","journal-title":"J Exp Med"},{"key":"8_CR144","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/eji.201344413","volume":"45","author":"ME Turnis","year":"2015","unstructured":"Turnis ME, Andrews LP, Vignali DAA (2015) Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol 45:1892\u20131905","journal-title":"Eur J Immunol"},{"key":"8_CR145","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s004280100458","volume":"440","author":"T Valkovic","year":"2002","unstructured":"Valkovic T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonjic N (2002) Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch 440:583\u2013588","journal-title":"Virchows Arch"},{"key":"8_CR146","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","volume":"131","author":"F Vari","year":"2018","unstructured":"Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, Cui Q, Han E, Tobin J, Bird R, Cross D, Hernandez A, Gould C, Birch S, Gandhi MK (2018) Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 131:1809\u20131819","journal-title":"Blood"},{"issue":"1035\u20131049","key":"8_CR147","first-page":"e19","volume":"177","author":"S Vasaikar","year":"2019","unstructured":"Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, Dou Y, Zhang Y, Shi Z, Arshad OA, Gritsenko MA, Zimmerman LJ, Mcdermott JE, Clauss TR, Moore RJ, Zhao R, Monroe ME, Wang YT, Chambers MC, Slebos RJC, Lau KS, Mo Q, Ding L, Ellis M, Thiagarajan M, Kinsinger CR, Rodriguez H, Smith RD, Rodland KD, Liebler DC, Liu T, Zhang B, Clinical Proteomic Tumor Analysis Consortium (2019) Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell 177(1035\u20131049):e19","journal-title":"Cell"},{"key":"8_CR148","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503","journal-title":"Nat Immunol"},{"key":"8_CR149","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaut.2013.06.006","volume":"45","author":"LSK Walker","year":"2013","unstructured":"Walker LSK (2013) Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun 45:49\u201357","journal-title":"J Autoimmun"},{"key":"8_CR150","doi-asserted-by":"crossref","unstructured":"Wallstabe L, Mades A, Frenz S, Einsele H, Rader C, Hudecek M (2018) CAR T cells targeting alphavbeta3 integrin are effective against advanced cancer in preclinical models. Adv Cell Gene Ther 1","DOI":"10.1002\/acg2.11"},{"key":"8_CR151","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00005-017-0463-9","volume":"65","author":"D Waniczek","year":"2017","unstructured":"Waniczek D, Lorenc Z, Snietura M, Wesecki M, Kopec A, Muc-Wierzgon M (2017) Tumor-associated macrophages and regulatory T cells infiltration and the clinical outcome in colorectal cancer. Arch Immunol Ther Exp 65:445\u2013454","journal-title":"Arch Immunol Ther Exp"},{"key":"8_CR152","doi-asserted-by":"crossref","unstructured":"Whilding ML, Halim L, Draper B, Parente-Pereira CA, Zabinski T, Davies MD, Maher J (2019) CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers:11","DOI":"10.3390\/cancers11050674"},{"key":"8_CR153","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nature10886","volume":"482","author":"B Wiedenheft","year":"2012","unstructured":"Wiedenheft B, Sternberg SH, Doudna JA (2012) RNA-guided genetic silencing systems in bacteria and archaea. Nature 482:331\u2013338","journal-title":"Nature"},{"key":"8_CR154","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, Mcarthur G, Lebb\u00e9 C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345\u20131356","journal-title":"N Engl J Med"},{"key":"8_CR155","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1042\/BST20150291","volume":"44","author":"OO Yeku","year":"2016","unstructured":"Yeku OO, Brentjens RJ (2016) Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans 44:412\u2013418","journal-title":"Biochem Soc Trans"},{"key":"8_CR156","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ (2017) Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 7:10541","journal-title":"Sci Rep"},{"key":"8_CR157","doi-asserted-by":"crossref","unstructured":"Yoon DH, Osborn MJ, Tolar J, Kim CJ (2018) Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T. Int J Mol Sci 19","DOI":"10.3390\/ijms19020340"},{"key":"8_CR158","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cytogfr.2009.11.009","volume":"21","author":"J Zhang","year":"2010","unstructured":"Zhang J, Patel L, Pienta KJ (2010) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21:41\u201348","journal-title":"Cytokine Growth Factor Rev"},{"key":"8_CR159","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/gt.2012.75","volume":"20","author":"L Zhang","year":"2013","unstructured":"Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA (2013) Inhibition of TGF-\u03b2 signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther 20:575\u2013580","journal-title":"Gene Ther"},{"key":"8_CR160","doi-asserted-by":"crossref","unstructured":"Zhang C, Burger MC, Jennewein L, Gen\u00dfler S, Sch\u00f6nfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP, Wels WS (2015a) ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma. JNCI: J Natl Cancer Inst 108","DOI":"10.1093\/jnci\/djv375"},{"key":"8_CR161","doi-asserted-by":"publisher","first-page":"33961","DOI":"10.18632\/oncotarget.5582","volume":"6","author":"T Zhang","year":"2015","unstructured":"Zhang T, Cao L, Xie J, Shi N, Zhang Z, Luo Z, Yue D, Zhang Z, Wang L, Han W, Xu Z, Chen H, Zhang Y (2015b) Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Oncotarget 6:33961\u201333971","journal-title":"Oncotarget"},{"key":"8_CR162","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","volume":"166","author":"H Zhang","year":"2016","unstructured":"Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, Mcdermott JE, Zhou JY, Petyuk VA, Chen L, Ray D, Sun S, Yang F, Chen L, Wang J, Shah P, Cha SW, Aiyetan P, Woo S, Tian Y, Gritsenko MA, Clauss TR, Choi C, Monroe ME, Thomas S, Nie S, Wu C, Moore RJ, Yu KH, Tabb DL, Fenyo D, Bafna V, Wang Y, Rodriguez H, Boja ES, Hiltke T, Rivers RC, Sokoll L, Zhu H, Shih IM, Cope L, Pandey A, Zhang B, Snyder MP, Levine DA, Smith RD, Chan DW, Rodland KD (2016) Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166:755\u2013765","journal-title":"Cell"},{"key":"8_CR163","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","volume":"11","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang X, Cheng C, Mu W, Liu X, Li N, Wei X, Liu X, Xia C, Wang H (2017) CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med 11:554\u2013562","journal-title":"Front Med"},{"key":"8_CR164","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-018-0759-3","volume":"17","author":"E Zhang","year":"2018","unstructured":"Zhang E, Gu J, Xu H (2018) Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer 17:7","journal-title":"Mol Cancer"},{"key":"8_CR165","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, Van Der Stegen SJC, Perna F, Kloss CC, Gunset G, Plotkin J, Sadelain M (2015) Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28:415\u2013428","journal-title":"Cancer Cell"},{"key":"8_CR166","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"XS Zhong","year":"2010","unstructured":"Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M (2010) Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 18:413\u2013420","journal-title":"Mol Ther"},{"key":"8_CR167","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.3892\/or.2016.5136","volume":"36","author":"Q Zhu","year":"2016","unstructured":"Zhu Q, Wu X, Wu Y, Wang X (2016) Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Oncol Rep 36:3472\u20133478","journal-title":"Oncol Rep"}],"container-title":["Advances in Experimental Medicine and Biology","Tumor Microenvironment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-44518-8_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:08:00Z","timestamp":1696288080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-44518-8_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030445171","9783030445188"],"references-count":168,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-44518-8_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"26 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}